⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707754 | 0.91 | BRD4 (0.50) | — | |
| SCHEMBL18566781 | 0.83 | BRD4 (0.44) | — | |
| SCHEMBL89034 | 0.83 | BRD4 (0.44) | — | |
| SCHEMBL17322742 | 0.82 | CHRNB2 (0.57) | — | |
| SCHEMBL14712106 | 0.82 | TP53 (0.52) | — | |
| SCHEMBL14711275 | 0.82 | TP53 (0.52) | — | |
| SCHEMBL7853872 | 0.82 | TP53 (0.52) | — | |
| SCHEMBL21910059 | 0.82 | BRD4 (0.43) | — | |
| SCHEMBL19334293 | 0.80 | BRD4 (0.42) | — | |
| SCHEMBL9052263 | 0.80 | SLC6A2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023072257-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-04 | — | — | WO | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3932404-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-20210163494-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180016265-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| US-9809582-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-07 | — | — | US | disclosed |
| WO-2017117528-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-07-06 | — | — | WO | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |